CIPRODEX- ciprofloxacin and dexamethasone suspension/ drops

CIPRODEX by

Drug Labeling and Warnings

CIPRODEX by is a Prescription medication manufactured, distributed, or labeled by Novartis Pharmaceuticals Corporation. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1     INDICATIONS AND USAGE

    CIPRODEX® is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below:

    • Acute Otitis Media (AOM) in pediatric patients (age 6 months and older) with tympanostomy tubes due to Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Pseudomonas aeruginosa.
    • Acute Otitis Externa (AOE) in pediatric (age 6 months and older), adult and elderly patients due to Staphylococcus aureus and Pseudomonas aeruginosa.
  • 2     DOSAGE AND ADMINISTRATION

    2.1     Important Administration Instructions

    • CIPRODEX is for otic use (ears) only, and not for ophthalmic use, or for injection.
    • Shake well immediately before use.

    2.2     Dosage

    For the Treatment of Acute Otitis Media in Pediatric Patients (age 6 months and older) With Tympanostomy Tubes

    The recommended dosage regimen through tympanostomy tubes is as follows:

    • Four drops [equivalent to 0.14 mL of CIPRODEX, (consisting of 0.42 mg of ciprofloxacin and 0.14 mg of dexamethasone)] instilled into the affected ear twice daily for seven days.
    • The suspension should be warmed by holding the bottle in the hand for one or two minutes to avoid dizziness, which may result from the instillation of a cold suspension.
    • The patient should lie with the affected ear upward, and then the drops should be instilled.
    • The tragus should then be pumped 5 times by pushing inward to facilitate penetration of the drops into the middle ear.
    • This position should be maintained for 60 seconds. Repeat, if necessary, for the opposite ear.
    • Discard unused portion after therapy is completed.

    For the Treatment of Acute Otitis Externa (age 6 months and older)

    The recommended dosage regimen is as follows:

    • Four drops [equivalent to 0.14 mL of CIPRODEX, (consisting of 0.42 mg ciprofloxacin and 0.14 mg dexamethasone)] instilled into the affected ear twice daily for seven days.
    • The suspension should be warmed by holding the bottle in the hand for one or two minutes to avoid dizziness, which may result from the instillation of a cold suspension.
    • The patient should lie with the affected ear upward, and then the drops should be instilled.
    • This position should be maintained for 60 seconds to facilitate penetration of the drops into the ear canal. Repeat, if necessary, for the opposite ear.
    • Discard unused portion after therapy is completed.
  • 3     DOSAGE FORMS AND STRENGTHS

    Otic Suspension: Each mL of CIPRODEX contains ciprofloxacin hydrochloride 0.3% (equivalent to 3 mg ciprofloxacin base) and dexamethasone 0.1% equivalent to 1 mg dexamethasone.

  • 4     CONTRAINDICATIONS

    • CIPRODEX is contraindicated in patients with a history of hypersensitivity to ciprofloxacin, to other quinolones, or to any of the components in this medication.
    • Use of this product is contraindicated in viral infections of the external canal, including herpes simplex infections and fungal otic infections.
  • 5     WARNINGS AND PRECAUTIONS

    5.1     Hypersensitivity Reactions

    CIPRODEX should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity. Serious and occasionally fatal hypersensitivity (anaphylactic) reactions, some following the first dose, have been reported in patients receiving systemic quinolones. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal, or facial edema), airway obstruction, dyspnea, urticaria, and itching.

    5.2     Potential for Microbial Overgrowth with Prolonged Use

    Prolonged use of CIPRODEX may result in overgrowth of non-susceptible bacteria and fungi. If the infection is not improved after one week of treatment, cultures should be obtained to guide further treatment. If such infections occur, discontinue use and institute alternative therapy.

    5.3     Continued or Recurrent Otorrhea

    If otorrhea persists after a full course of therapy, or if two or more episodes of otorrhea occur within six months, further evaluation is recommended to exclude an underlying condition, such as cholesteatoma, foreign body, or a tumor.

  • 6     ADVERSE REACTIONS

    The following serious adverse reactions are described elsewhere in the labeling:

    • Hypersensitivity Reactions [see Warnings and Precautions (5.1)]
    • Potential for Microbial Overgrowth with Prolonged Use [see Warnings and Precautions (5.2)]

    6.1     Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in practice.

    In Phases II and III clinical trials, a total of 937 patients were treated with CIPRODEX. This included 400 patients with acute otitis media with tympanostomy tubes (AOMT) and 537 patients with AOE. The reported adverse reactions are listed below:

    Acute Otitis Media in Pediatric Patients with Tympanostomy Tubes

    The following adverse reactions occurred in 0.5% or more of the patients with non-intact tympanic membranes.

    Adverse ReactionsIncidence (N = 400)
    Ear discomfort3.0%
    Ear pain2.3%
    Ear precipitate (residue)0.5%
    Irritability0.5%
    Taste Perversion0.5%

    The following adverse reactions were each reported in a single patient: tympanostomy tube blockage; ear pruritus; tinnitus; oral moniliasis; crying; dizziness; and erythema.

    Acute Otitis Externa

    The following adverse reactions occurred in 0.4% or more of the patients with intact tympanic membranes.

    Adverse ReactionsIncidence (N = 537)
    Ear pruritus1.5%
    Ear debris0.6%
    Superimposed ear infection0.6%
    Ear congestion0.4%
    Ear pain0.4%
    Erythema 0.4%

    The following adverse reactions were each reported in a single patient: ear discomfort; decreased hearing; and ear disorder (tingling).

    6.2     Postmarketing Experience

    The following adverse reactions have been identified during post approval use of CIPRODEX. Because these reactions are reported voluntarily from a population of unknown size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These reactions include auricular swelling, headache, hypersensitivity, otorrhea, skin exfoliation, rash erythematous, and vomiting.

  • 8     USE IN SPECIFIC POPULATIONS

    8.1     Pregnancy

    Risk Summary

    There are no available data on CIPRODEX use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal, or fetal outcomes. Because of the minimal systemic absorption of ciprofloxacin and dexamethasone following topical otic administration of CIPRODEX, this product is expected to be of minimal risk for maternal and fetal toxicity when administered to pregnant women [see Clinical Pharmacology (12.3)].

    Animal reproduction studies have not been conducted with CIPRODEX. Oral administration of ciprofloxacin during organogenesis at doses up to 100 mg/kg to pregnant mice and rats, and up to 30 mg/kg to pregnant rabbits did not cause fetal malformations (see Data). These doses were at least 200 times the recommended otic human dose (ROHD in mice, rats, and rabbits, respectively, based on body surface area (BSA). With dexamethasone, malformations have been observed in animal studies after ocular and systemic administration.

    The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and of miscarriage is 15% to 20%, respectively.

    Data

    Animal Data

    Ciprofloxacin

    Developmental toxicology studies have been performed with ciprofloxacin in rats, mice, and rabbits. The doses used in these studies are, at a minimum, approximately 200 times greater than the recommended otic human dose based on body surface area. In rats and mice, oral doses up to 100 mg/kg administered during organogenesis (Gestation Days [GD], 6-17) were not associated with adverse developmental outcomes, including embryofetal toxicity or malformations. A 30 mg/kg oral dose was associated with suppression of maternal and fetal body weight gain, but fetal malformations were not observed. Intravenous administration of doses up to 20 mg/kg to pregnant rabbits was not maternally toxic and neither embryo-fetal toxicity nor fetal malformations were observed. To mitigate maternal toxicity in these studies, groups of rabbits received ciprofloxacin for a different 5 day dosing period covering organogenesis (GD 6-18).

    Dexamethasone

    Dexamethasone has been shown to be teratogenic in mice and rabbits following topical ophthalmic application. In a rat oral developmental toxicity study, no adverse effects were observed at 0.01 mg/kg/day (0.1 times the ROHD based on BSA), although embryotoxicity was observed at higher doses.

    8.2     Lactation

    Risk Summary

    It is not known whether ciprofloxacin and dexamethasone are present in human milk following topical otic administration.

    Published literature reports the presence of ciprofloxacin in human milk after oral administration to lactating women. However, because of the minimal systemic absorption of ciprofloxacin following topical otic administration of CIPRODEX, breastfeeding is not expected to result in the exposure of the infant to ciprofloxacin [see Clinical Pharmacology (12.3)].

    Systemically administered corticosteroids appear in human milk. Dexamethasone in breast milk could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. However, it is not known whether topical otic administration of CIPRODEX could result in systemic absorption that is sufficient to produce detectable quantities of dexamethasone in human milk.

    There are no data on the effects of ciprofloxacin or dexamethasone on milk production.

    The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for CIPRODEX and any potential adverse effects on the breast-fed child from CIPRODEX.

    8.4     Pediatric Use

    The safety and efficacy of CIPRODEX have been established in pediatric patients 6 months and older (937 patients) in adequate and well-controlled clinical trials.

    No clinically relevant changes in hearing function were observed in 69 pediatric patients (age 4 to 12 years) treated with CIPRODEX and tested for audiometric parameters.

  • 10     OVERDOSAGE

    Due to the characteristics of this preparation, no toxic effects are to be expected with an otic overdose of this product.

  • 11     DESCRIPTION

    CIPRODEX (ciprofloxacin 0.3% and dexamethasone 0.1%) Sterile Otic Suspension contains the quinolone antimicrobial, ciprofloxacin hydrochloride, combined with the corticosteroid, dexamethasone, in a sterile, preserved suspension for otic use. Each mL of CIPRODEX contains ciprofloxacin hydrochloride (equivalent to 3 mg ciprofloxacin base), 1 mg dexamethasone, and 0.1 mg benzalkonium chloride as a preservative. The inactive ingredients are acetic acid, boric acid, edetate disodium, hydroxyethyl cellulose, purified water, sodium acetate, sodium chloride, and tyloxapol. Sodium hydroxide or hydrochloric acid may be added for adjustment of pH.

    Ciprofloxacin, a quinolone antimicrobial is available as the monohydrochloride monohydrate salt of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline carboxylic acid. The empirical formula is C17H18FN3O3·HCl·H2O. The molecular weight is 385.82 g/mol and the structural formula is:

    Figure 1: Structure of Ciprofloxacin

    Figure 1: Structure of Ciprofloxacin

    Dexamethasone, 9-fluoro-11(beta),17,21-trihydroxy-16(alpha)-methylpregna-1,4-diene-3,20-dione, is a corticosteroid. The empirical formula is C22H29FO5. The molecular weight is 392.46 g/mol and the structural formula is:

    Figure 2: Structure of Dexamethasone

    Figure 2: Structure of Dexamethasone

  • 12     CLINICAL PHARMACOLOGY

    12.1     Mechanism of Action

    Ciprofloxacin is a fluoroquinolone antibacterial [see Microbiology (12.4)].

    Dexamethasone, a corticosteroid, has been shown to suppress inflammation by inhibiting multiple inflammatory cytokines resulting in decreased edema, fibrin deposition, capillary leakage, and migration of inflammatory cells.

    12.3     Pharmacokinetics

    Following a single bilateral 4-drop (total dose = 0.28 mL, 0.84 mg ciprofloxacin, 0.28 mg dexamethasone) topical otic dose of CIPRODEX to pediatric patients after tympanostomy tube insertion, measurable plasma concentrations of ciprofloxacin and dexamethasone were observed at 6 hours following administration in 2 of 9 patients and 5 of 9 patients, respectively.

    Mean ± SD peak plasma concentrations of ciprofloxacin were 1.39 ± 0.880 ng/mL (n = 9). Peak plasma concentrations ranged from 0.543 ng/mL to 3.45 ng/mL and were on average approximately 0.1% of peak plasma concentrations achieved with an oral dose of 250-mg. Peak plasma concentrations of ciprofloxacin were observed within 15 minutes to 2 hours post dose application.

    Mean ± SD peak plasma concentrations of dexamethasone were 1.14 ± 1.54 ng/mL (n = 9). Peak plasma concentrations ranged from 0.135 ng/mL to 5.10 ng/mL and were on average approximately 14% of peak concentrations reported in the literature following an oral 0.5-mg tablet dose. Peak plasma concentrations of dexamethasone were observed within 15 minutes to 2 hours post dose application.

    Dexamethasone has been added to aid in the resolution of the inflammatory response accompanying bacterial infection (such as otorrhea in pediatric patients with AOMT).

    12.4     Microbiology

    Mechanism of Action
    The bactericidal action of ciprofloxacin results from interference with the enzyme, DNA gyrase, which is needed for the synthesis of bacterial DNA.

    Resistance
    Cross-resistance has been observed between ciprofloxacin and other fluoroquinolones. There is generally no cross-resistance between ciprofloxacin and other classes of anti-bacterial agents, such as beta-lactams or aminoglycosides.

    Antimicrobial Activity
    Ciprofloxacin has been shown to be active against most isolates of the following microorganisms, both in vitro and clinically in otic infections [see Indications and Usage (1)].

    Aerobic Bacteria
    Gram-positive Bacteria

    • Staphylococcus aureus
    • Streptococcus pneumoniae

    Gram-negative Bacteria

    • Haemophilus influenzae
    • Moraxella catarrhalis
    • Pseudomonas aeruginosa
  • 13     NONCLINICAL TOXICOLOGY

    13.1     Carcinogenesis, Mutagenesis, Impairment of Fertility

    Carcinogenesis

    Long-term carcinogenicity studies in mice and rats have been completed for ciprofloxacin. After daily oral doses of 750 mg/kg (mice) and 250 mg/kg (rats) were administered for up to 2 years, there was no evidence that ciprofloxacin had any carcinogenic or tumorigenic effects in these species. No long-term studies of CIPRODEX have been performed to evaluate carcinogenic potential.

    Long-term studies have not been performed to evaluate the carcinogenic potential of topical otic dexamethasone.

    Mutagenesis

    Eight in vitro mutagenicity tests have been conducted with ciprofloxacin, and the test results are listed below:

    • Salmonella/Microsome Test (Negative)
    • E. coli DNA Repair Assay (Negative)
    • Mouse Lymphoma Cell Forward Mutation Assay (Positive)
    • Chinese Hamster V79 Cell HGPRT Test (Negative)
    • Syrian Hamster Embryo Cell Transformation Assay (Negative)
    • Saccharomyces cerevisiae Point Mutation Assay (Negative)
    • Saccharomyces cerevisiae Mitotic Crossover and Gene Conversion Assay (Negative)
    • Rat Hepatocyte DNA Repair Assay (Positive)

    Thus, 2 of the 8 tests were positive, but results of the following 3 in vivo test systems gave negative results:

    • Rat Hepatocyte DNA Repair Assay
    • Micronucleus Test (Mice)
    • Dominant Lethal Test (Mice)

    Dexamethasone has been tested for in vitro and in vivo genotoxic potential and shown to be positive in the following assays: chromosomal aberrations, sister-chromatid exchange in human lymphocytes, and micronuclei and sister-chromatid exchanges in mouse bone marrow. However, the Ames/Salmonella assay, both with and without S9 mix, did not show any increase in His+ revertants.

    Impairment of Fertility

    Fertility studies performed in male and female rats at oral doses of ciprofloxacin up to 100 mg/kg (approximately 482 times the ROHD of ciprofloxacin based on BSA) revealed no evidence of impairment. Male rats received oral ciprofloxacin for 10 weeks prior to mating and females were dosed for 3 weeks prior to mating through GD 7.

    The effect of dexamethasone on fertility has not been investigated following topical otic application. However, the lowest toxic dose of dexamethasone identified following topical dermal application was 1.802 mg/kg in a 26-week study in male rats and resulted in changes to the testes, epididymis, sperm duct, prostate, seminal vesicle, Cowper's gland, and accessory glands. The relevance of this study for short-term topical otic use is unknown.

    13.2     Animal Toxicology and/or Pharmacology

    Guinea pigs dosed in the middle ear with CIPRODEX for one month exhibited no drug-related structural or functional changes of the cochlear hair cells and no lesions in the ossicles.

  • 14     CLINICAL STUDIES

    In a randomized, multicenter, controlled clinical trial, CIPRODEX dosed 2 times per day for 7 days demonstrated clinical cures in the per protocol analysis in 86% of AOMT patients compared to 79% for ofloxacin solution, 0.3%, dosed 2 times per day for 10 days. Among culture positive patients, clinical cures were 90% for CIPRODEX compared to 79% for ofloxacin solution, 0.3%. Microbiological eradication rates for these patients in the same clinical trial were 91% for CIPRODEX compared to 82% for ofloxacin solution, 0.3%.

    In 2 randomized multicenter, controlled clinical trials, CIPRODEX dosed 2 times per day for 7 days demonstrated clinical cures in 87% and 94% of per protocol evaluable AOE patients, respectively, compared to 84% and 89%, respectively, for otic suspension containing neomycin 0.35%, polymyxin B 10,000 units/mL, and hydrocortisone 1.0% (neo/poly/HC). Among culture-positive patients, clinical cures were 86% and 92% for CIPRODEX compared to 84% and 89%, respectively, for neo/poly/HC. Microbiological eradication rates for these patients in the same clinical trials were 86% and 92% for CIPRODEX compared to 85% and 85%, respectively, for neo/poly/HC.

  • 16     HOW SUPPLIED/STORAGE AND HANDLING

    How Supplied

    CIPRODEX (ciprofloxacin 0.3% and dexamethasone 0.1%) Sterile Otic Suspension is a white-to off-white suspension supplied as follows: 7.5 mL fill in a system consisting of a natural polyethylene bottle and natural plug, with a white polypropylene closure. Tamper evidence is provided with a shrink band around the closure and neck area of the package.

    7.5 mL fill          NDC: 0078-0799-75

    Storage

    Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature].

    Avoid freezing. Protect from light.

  • 17     PATIENT COUNSELING INFORMATION

    Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

    For Otic Use Only

    Advise patients that CIPRODEX is for otic use (ears) only. This product must not be used in the eye [see Dosage and Administration (2.2)].

    Administration Instructions

    Instruct patients to warm the bottle in their hand for one to two minutes prior to use and shake well immediately before using [see Dosage and Administration (2.1, 2.2)].

    Allergic Reactions

    Advise patients to discontinue use immediately and contact their physician, if rash or allergic reaction occurs [see Warnings and Precautions (5.1)].

    Avoid Contamination of the Product

    Advise patients to avoid contaminating the tip with material from the ear, fingers, or other sources [see Instructions for Use].

    Duration of Use

    Advise patients that it is very important to use the eardrops for as long as their doctor has instructed, even if the symptoms improve [see Patient Information].

    Protect from Light

    Advise patients to protect the product from light [see How Supplied/Storage and Handling (16)].

    Unused Product

    Advise patients to discard unused portion after therapy is completed [see Dosage and Administration (2.2)].

    Distributed by:
    Novartis Pharmaceuticals Corporation
    East Hanover, New Jersey 07936


    T2020-141

  • PATIENT PACKAGE INSERT

    This Patient Information has been approved by the U.S. Food and Drug Administration.Revised: November 2020
    PATIENT INFORMATION
    CIPRODEX® (CI-PRO-DEX)
    (ciprofloxacin and dexamethasone)
    otic suspension
    What is CIPRODEX?
    CIPRODEX is a prescription medicine used in the ear only (otic use) that contains 2 medicines, a quinolone antibiotic medicine called ciprofloxacin and a corticosteroid medicine called dexamethasone. CIPRODEX is used in adults and children 6 months of age or older to treat certain types of infections caused by certain germs called bacteria. These bacterial infections include:
    • middle ear infection (known as acute otitis media or AOM) in people who have a tube in their eardrum known as a tympanostomy to prevent having too much fluid in the middle ear
    • outer ear canal infection (known as acute otitis externa or AOE)
    It is not known if CIPRODEX is safe and effective in children under 6 months of age.
    Who should not use CIPRODEX?
    Do not use CIPRODEX if you:
    • are allergic to ciprofloxacin, quinolones, or any of the ingredients in CIPRODEX. See the end of this Patient Information leaflet for a complete list of ingredients in CIPRODEX.
    • have an outer ear canal infection caused by certain viruses, including the herpes simplex virus.
    • have an ear infection caused by a fungus.
    What should I tell my doctor before using CIPRODEX?
    Before using CIPRODEX, tell your doctor about all of your medical conditions, including if you:
    • are pregnant or plan to become pregnant. It is not known if CIPRODEX will harm your unborn baby.
    • are breastfeeding or plan to breastfeed. It is not known if CIPRODEX passes into your breast milk. Talk to your doctor about the best way to feed your baby during treatment with CIPRODEX. Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
    How should I use CIPRODEX?
    • Read the detailed Instructions for Use that come with CIPRODEX.
    • Use CIPRODEX exactly as your doctor tells you to.
    • CIPRODEX is for use in the ear only (otic use). Do not use CIPRODEX in the eye or inject CIPRODEX.
    • Apply 4 drops of CIPRODEX into the affected ear 2 times a day for 7 days.
    • Do not stop using CIPRODEX unless your doctor tells you to, even if your symptoms improve.
    If your symptoms do not improve after 7 days of treatment with CIPRODEX, call your doctor.
    • Call your doctor right away if:
      • you have fluid that continues to drain from your ear (otorrhea) after you have finished your treatment with CIPRODEX
      • you have fluid that drains from your ear 2 or more times within 6 months after you stop treatment with CIPRODEX
    What are the possible side effects of CIPRODEX?
    CIPRODEX may cause serious side effects, including:
    • allergic reactions. Stop using CIPRODEX and call your doctor or go to the nearest emergency room if you have any of the following signs or symptoms of an allergic reaction:
    • hives (urticaria)
    • swelling of your face, lips, mouth, or tongue
    • rash
    • itching
    • trouble breathing
    • dizziness, fast heartbeat, or pounding in your chest
    The most common side effects of CIPRODEX include:
    • ear discomfort
    • ear pain
    • ear itching (pruritus)
    These are not all the possible side effects of CIPRODEX. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
    How should I store CIPRODEX?
    • Store CIPRODEX at room temperature between 68°F to 77°F (20°C to 25°C).
    • Do not freeze CIPRODEX.
    • Keep CIPRODEX out of light.
    Keep CIPRODEX and all medicines out of the reach of children.
    General information about the safe and effective use of CIPRODEX.
    Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use CIPRODEX for a condition for which it was not prescribed. Do not give CIPRODEX to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or doctor for information about CIPRODEX that is written for health professionals.
    What are the ingredients in CIPRODEX?
    Active ingredients: ciprofloxacin hydrochloride, dexamethasone, and benzalkonium chloride as a preservative
    Inactive ingredients: acetic acid, boric acid, edetate disodium, hydroxyethyl cellulose, purified water, sodium acetate, sodium chloride, and tyloxapol. Sodium hydroxide or hydrochloric acid may be added for adjustment of pH.

    Distributed by:
    Novartis Pharmaceuticals Corporation
    East Hanover, New Jersey 07936

    © Novartis

    T2020-142

  • INSTRUCTIONS FOR USE

    This Instructions for Use has been approved by the U.S. Food and Drug Administration.Revised: November 2020
    INSTRUCTIONS FOR USE
    CIPRODEX® (CI-PRO-DEX)
    (ciprofloxacin and dexamethasone)
    otic suspension
    This “Instructions for Use” contains information on how to use CIPRODEX.
    Important Information You Need to Know Before Using CIPRODEX.
    Read this Instructions for Use that comes with CIPRODEX before you start using it and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or treatment.
    • Use CIPRODEX exactly as your doctor tells you to use it.
    • CIPRODEX is for use in the ear only (otic use). Do not inject CIPRODEX or use CIPRODEX in the eye.
    • Shake CIPRODEX well before each use.
    • Do not touch your ear, fingers, or other surfaces with the tip of the CIPRODEX bottle. You may get bacteria on the tip of the bottle that can cause you to get another infection.
    How should I use CIPRODEX?
    Step 1. Wash your hands with soap and water (see Figure A).
    Figure A
    wash
    Step 2. Warm the bottle of CIPRODEX by rolling the bottle between your hands for 1 to 2 minutes (see Figure B). Shake the bottle of CIPRODEX well.
    Figure B
    warm

    Step 3. Remove the CIPRODEX cap. Put the cap in a clean and dry area. Do not let the tip of the bottle touch your ear, fingers or other surfaces.

    Step 4. Lie down on your side so that the affected ear faces upward (see Figure C).
    Figure C
    sick

    Step 5. Hold the bottle of CIPRODEX between your thumb and index finger (see Figure D). Place the tip of the bottle close to your ear. Be careful not to touch your fingers or ear with the tip of the bottle.
    Figure D
    eardrop

    Step 6    . Gently squeeze the bottle and let 4 drops of CIPRODEX fall into the affected ear. If a drop misses your ear, follow the instructions in Step 5 again.

    Step 7. Stay on your side     with the affected ear facing upward (see Figure C).
    It is important that you follow the instructions below for your specific ear infection, to allow CIPRODEX to enter the affected part of your ear.

    Step 8. If you use CIPRODEX to treat a middle ear infection, and you have a tube in your eardrum known as a tympanostomy:
    • Gently press the part of the ear known as the tragus (see Figure E) 5 times using a pumping motion (see Figure E). This will allow the drops of CIPRODEX to enter your middle ear.
    • Remain on your side with the affected ear facing upward (see Figure C) for 1 minute.
    Figure E
    tragus

    If you use CIPRODEX to treat an outer ear canal infection:
    • Gently pull the outer ear lobe upward and backward (see Figure F). This will allow the drops of CIPRODEX to enter your ear canal.
    • Remain on your side with the affected ear facing upward (see Figure C) for 1 minute.
    Figure F
    up back

    Step 9. If your doctor has told you to use CIPRODEX in both ears, repeat steps 5-8 for your other ear.

    Step 10. Put the cap back on the bottle and close it tightly.

    Step 11. After you have used all of your CIPRODEX doses, there may be some CIPRODEX left in the bottle. Throw the bottle away.
    How should I store CIPRODEX?
    • Store CIPRODEX at room temperature between 68°F to 77°F (20°C to 25°C).
    • Do not freeze CIPRODEX.
    • Keep CIPRODEX out of light.
    Keep CIPRODEX and all medicines out of the reach of children.
    If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for more information about CIPRODEX that is written for health professionals.
    Distributed by:
    Novartis Pharmaceuticals Corporation
    East Hanover, New Jersey 07936

    © Novartis

    T2020-143

  • PRINCIPAL DISPLAY PANEL

    NDC: 0078-0799-75

    Rx Only

    CIPRODEX®

    (ciprofloxacin 0.3% and dexamethasone 0.1%)

    STERILE OTIC SUSPENSION

    FOR USE IN EARS ONLY

    7.5 mL

    NOVARTIS

    NDC: <a href=/NDC/0078-0799-75>0078-0799-75</a> Rx Only CIPRODEX® (ciprofloxacin 0.3% and dexamethasone 0.1%) STERILE OTIC SUSPENSION FOR USE IN EARS ONLY 7.5 mL NOVARTIS
  • INGREDIENTS AND APPEARANCE
    CIPRODEX 
    ciprofloxacin and dexamethasone suspension/ drops
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 0078-0799
    Route of AdministrationAURICULAR (OTIC)
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    Ciprofloxacin Hydrochloride (UNII: 4BA73M5E37) (Ciprofloxacin - UNII:5E8K9I0O4U) Ciprofloxacin3 mg  in 1 mL
    Dexamethasone (UNII: 7S5I7G3JQL) (Dexamethasone - UNII:7S5I7G3JQL) Dexamethasone1 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    Benzalkonium Chloride (UNII: F5UM2KM3W7)  
    Boric Acid (UNII: R57ZHV85D4)  
    Sodium Chloride (UNII: 451W47IQ8X)  
    Hydroxyethyl Cellulose (1500 Mpa.s At 1%) (UNII: L605B5892V)  
    Tyloxapol (UNII: Y27PUL9H56)  
    Acetic Acid (UNII: Q40Q9N063P)  
    Sodium Acetate (UNII: 4550K0SC9B)  
    Edetate Disodium (UNII: 7FLD91C86K)  
    Water (UNII: 059QF0KO0R)  
    Sodium Hydroxide (UNII: 55X04QC32I)  
    Hydrochloric Acid (UNII: QTT17582CB)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 0078-0799-751 in 1 CARTON07/28/2020
    17.5 mL in 1 BOTTLE; Type 0: Not a Combination Product
    2NDC: 0078-0799-981 in 1 CARTON07/28/202001/31/2021
    20.5 mL in 1 BOTTLE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    NDANDA02153708/04/2003
    Labeler - Novartis Pharmaceuticals Corporation (002147023)

    • Trademark Results [CIPRODEX]

    Mark Image

    Registration | Serial
    Company
    Trademark
    Application Date
    CIPRODEX
    CIPRODEX
    75935885 2513415 Live/Registered
    Bayer Aktiengesellschaft
    2000-03-06
    © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.